Purpose: The aim of this study was to assess the effect of donor and recipient factors on corneal allograft rejection and evaluate whether a rejection event was associated with graft failure.
T he Cornea Donor Study (CDS) examined the relationship between donor age and long-term cornea transplant survival by following for up to 12 years a cohort of 1090 participants who underwent penetrating keratoplasty (PK), primarily for either Fuchs dystrophy or pseudophakic or aphakic corneal edema (PACE). At 10 years, there was no significant difference in graft survival between the 2 main donor age groups (12-65 years and 66-75 years), but there was a suggestion of a donor age effect at the extremes of the age range. 1 At 5 years, we assessed the effect of donor and recipient factors on corneal allograft rejection. Although graft rejection was not associated with donor age, female recipients were more likely than men to have a rejection event, and there was a substantially higher graft rejection rate in eyes with PACE compared with eyes with Fuchs dystrophy. 2 With 10 to 12 years of follow-up now completed, we have reassessed factors associated with graft rejection and have evaluated whether a rejection event was associated with subsequent graft failure.
MATERIALS AND METHODS

Study Protocol
The CDS study protocol, including the Specular Microscopy Ancillary Study protocol, has been previously described [3] [4] [5] and is briefly summarized here. Institutional review boards at each participating site approved the study protocol, and written consent was obtained from each participant. The 1090 eligible participants underwent PK at 80 sites for Fuchs dystrophy (62%), PACE (34%), or another corneal endothelial disorder (4%). The participants' median age at the time of transplant was 72 years (interquartile range, 65-76 years), and the donors' median age at the time of death was 61 years (interquartile range, 52-69 years). Surgeons and participants were masked to age and endothelial cell density of the donors. Corneal tissue assignment was made without regard to age or any other subject characteristics. Preoperative care, surgical technique, and postoperative care (including prescription of medications) were provided according to each surgeon's customary routine. The number and timing of visits for the first 6 months after PK were left to the discretion of each investigator. Thereafter, the minimum follow-up visit schedule included visits at 6 months, 1 year, and then annually for 10 to 12 years for participants who did not require a regraft.
A graft rejection was classified as definite when an endothelial rejection line was present in a graft that was previously clear and probable when there was inflammation (stromal infiltrate, keratic precipitates, cells in the anterior chamber, or ciliary injection) without an endothelial rejection line in a graft that was previously clear. A graft failure was defined as a regraft or loss of central graft clarity sufficient to compromise vision for a minimum of 3 consecutive months. Treatment of graft rejection was at the discretion of the investigator.
Statistical Methods
Analyses paralleled those reported after 5 years. Lifetable analysis was used to compute the probability of the first probable or definite rejection event according to the study examination schedule (6 months, 1 year, and annually thereafter through 10 years of follow-up). Data were censored at the time of a nonrejection graft failure or at the last examination. Associations of baseline recipient and donor factors with the occurrence of a definite rejection event were assessed in univariate and multivariate proportional hazards regression models. Missing covariates in the multivariate models were handled by including missing as a separate category for discrete covariates and adding an indicator for a missing value for continuous covariates. Covariates with P , 0.10 were included in the final recipient and donor multivariate models generated through stepwise selection to control for any potential confounding; however, only factors with P , 0.01 were considered statistically significant. The impact of a rejection event on graft failure from all causes was assessed by including graft rejection as a time-dependent variable for definite and probable rejection events in a proportional hazards regression model. Proportional hazards assumptions were checked and no significant deviation was detected for the final models. All reported P values are 2-sided. Statistical analyses were conducted using SAS versions 9.3 software (SAS Institute Inc, Cary, NC).
RESULTS
During follow-up, 133 of the 1090 participants (12%) had at least 1 definite rejection episode and an additional 175 (16%) had a probable rejection episode. The 10-year cumulative probability [699% confidence interval (CI)] for the first definite rejection event was 15% 6 3% and for the first definite or probable rejection event was 34% 6 4% ( Fig. 1 ). The 10-year cumulative probability of definite rejection varied by the type of corneal disorder: 21% 6 7% for PACE versus 13% 6 4% for Fuchs dystrophy (P = 0.002) ( Fig. 2 ). However, corneal diagnosis was confounded with glaucoma history (30% for PACE compared with 7% for Fuchs dystrophy; see Table, Supplemental Digital Content 1, http://links.lww.com/ICO/A236). In a multivariate model, corneal diagnosis when combined with lens status was no longer significant, and the only baseline factor significantly associated with a higher risk of definite graft rejection was a preoperative history of glaucoma, particularly when previous glaucoma surgery had been performed and glaucoma medications were being used at the time of transplant (10-year incidence 35% 6 23% compared with 14% 6 4% in eyes with no history of glaucoma/intraocular pressure treatment, P = 0.008; Fig. 3 and see Table, Supplemental Digital Content 2, http://links.lww.com/ICO/A237).
The occurrence of a rejection event increased the likelihood of subsequent graft failure. Among 651 eyes with a surviving graft at 5 years, the 10-year graft failure (699% CI) rates were 12% 6 4% among eyes with no rejection events in the first 5 years, 17% 6 12% in eyes with at least 1 probable, but no definite rejection event, and 22% 6 20% in eyes with at least 1 definite rejection event ( Fig. 4) . Similarly, in a Cox regression model including all 1090 eyes over 10 years of follow-up, the hazard ratio was 25.0 (99% CI, 16.4-38.0; P , 0.001) for the association of a previous definite rejection event as a time-dependent factor with subsequent graft failure and 6.1 (99% CI, 3.9-9.7; P , 0.001) for a probable rejection event ( Fig. 4) .
One hundred and thirty three patients (12%) experienced one or more definite rejection episodes during the follow-up period. Of these, 41 (31%) responded to treatment and maintained a clear transplant throughout follow-up. Further examination of the data related to patients experiencing a definite rejection showed that 22% of patients with PACE ultimately cleared as compared with 37% of patients with Fuchs dystrophy. These calculations are based on a strict definition of a rejection event. If both probable and definite rejection episodes were evaluated, giving us a more relaxed and "inclusive" definition of a rejection, the percentage who experienced one or more definite rejection episodes during the follow-up period increased to 28%, with 51% (158) responding to treatment and maintaining a clear corneal transplant. This breaks down to 57% of those with Fuchs dystrophy responding to treatment as compared with 43% responding with PACE.
DISCUSSION
The CDS sought to determine the impact of donor age on transplant success in a group of 1090 intermediate-risk corneal transplant patients who were followed up to 12 years. The results and analysis of this have been published. 1 The prospective format of the study also allowed data to be year results disclosed a statistically significant association between graft rejection and corneal diagnosis and female recipient gender. 2 At the same time, a statistically significant association between graft failure and corneal diagnosis, a history of glaucoma surgery, and, to a lesser extent, race was observed. 6 The extended follow-up of this population has allowed us to reassess these findings and to focus the relationship between previously identified risk factors and the likelihood of a rejection event progressing to graft failure. The cumulative probability of definite rejection was 10% during the first 5-year period, and this increased to 15% by the end of the 10-year follow-up period. Further breakdown according to recipient diagnosis indicated that the cumulative probability of a rejection event among patients with Fuchs dystrophy was 13% and increased to 21% among those with PACE. The increased probability of a rejection event among the PACE group at 10 years was consistent with the pattern previously noted in the 5-year follow-up results. 2 Ing et al 7 reported the 10 years rejection probability of patients undergoing PK for pseudophakic corneal edema, aphakic corneal edema, and Fuchs dystrophy as 21%, 28%, and 21%, respectively. Their values were more uniform between study groups and noticeably higher in patients with Fuchs dystrophy as compared with similar measures in the CDS. The cumulative probability, when reassessed in the same patient cohort at 15 years, did not differ between preoperative diagnoses. 8 In the CDS, lens status in patients with Fuchs dystrophy did not seem to influence the cumulative probability of a rejection event at 10 years (12%-13%). The disparity in the rejection rates between patients with Fuchs dystrophy with intraocular lenses and those with pseudophakic corneal edema suggests that differences in the intraocular lenses used, the status of the vitreous, presence of a peripheral iridectomy, iridocorneal adhesions or the possibility of greater operative or postoperative complications (at the time of primary cataract surgery) might have impacted the intraocular microenvironment permanently. Those in the PACE group did have a higher incidence of glaucoma, which was also identified as an independent risk factor for rejection in multivariate analysis. Although general information regarding steroid use was documented, the CDS did not collect sufficient data to determine whether the specific steroid used (ie, prednisolone acetate vs. fluorometholone), the dosing schedule, or the cessation of steroids altogether had any impact on the frequency of rejection episodes.
Preexisting glaucoma is a recognized risk factor for graft failure, but few studies have studied its relationship to graft rejection. 7, [9] [10] [11] [12] [13] [14] Baseline CDS patient data indicated that 30% of those with PACE were on glaucoma medications, had a history of glaucoma surgery (drainage devices/shunts were excluded), or both at the start of the study as compared with 7% of those with Fuchs dystrophy. This pattern has been observed in other studies that assessed preoperative and postoperative glaucoma in patients with PK. 10, 11 While not segregating the data according to diagnosis, multivariate analysis did find a significant increase in definite rejection events in patients who were using glaucoma medications and had previous glaucoma surgery (35% incidence vs. 14% if no glaucoma medications or surgery had been performed) (P = 0.008). No association, however, was found between graft rejection and postoperative IOP control. The CDS made no attempt to document how advanced the glaucoma was; however, it is reasonable to assume that patients who require both glaucoma medications and surgery would have moderate or more advanced disease.
Glaucoma filtering and drainage device surgery have been associated with an increased risk of corneal transplant rejection and failure when performed after PK. [15] [16] [17] [18] Presumably, this is related to the effect of operative and postoperative trauma and inflammation on the transplant. The influence of glaucoma filtering surgery before PK on the incidence of a rejection reaction has not been previously reported. Patients with uncontrolled glaucoma or previous glaucoma filtering surgery where a drainage shunt was placed were excluded from the CDS. Data analysis of baseline recipient and donor factors indicated a relationship with the combination of previous glaucoma surgery and glaucoma medications.
A concern that glaucoma medications may interfere with endothelial function has been raised in the past. Studies that have focused endothelial status using specular microscopy, pachymetry, and fluorophotometry after extended clinical use of topical bromonidine, beta-blockers, dorzolamide, and prostaglandin analogs have shown no significant alterations. 15, [18] [19] [20] These studies were generally performed in normal subjects or those with mild endothelial changes and may not apply to patients with advanced endothelial disease and/or decompensation. Glaucoma medications, either directly or using preservatives such as benzalkonium chloride, have been shown to trigger inflammatory changes within the conjunctiva and adversely alter the tear film and ocular surface. Increased expression of conjunctival and tear proinflammatory cytokines (IL-1, Il-6, Il-8, TNF-a) as well as HLA-DR and ICAM-1 have been associated with chronic antiglaucoma medication usage. [21] [22] [23] Anterior chamber flare has also been reported. 24 It is unknown whether these effects are amplified after glaucoma filtering surgery. Inflammatory changes induced through these mechanisms may explain the CDS findings of an increased incidence of rejection events in patients taking glaucoma medications and having undergone previous glaucoma filtering surgery. The impact of topical steroids (length of time used, potency, and frequency) on this observation could not be assessed.
In a single-center 5-year follow-up series that studied risk factors associated with graft failure in first-time corneal grafts (43.9% with PACE and 24.9% with Fuchs dystrophy), Price et al 25 found an association between glaucoma medication use and graft rejection and failure from immunologic and nonimmunologic causes. A lower incidence of glaucoma in their study population (15%) and a different definition of glaucoma (glaucoma defined by the use of antiglaucoma medications only, without regard to previous glaucoma surgery) may account for the lower rejection and graft failure rates (all causes) of 2.1% and 7.5%, respectively. The impact of steroids on the results of these studies could not be determined.
Donor tissue in the CDS was distributed randomly without regard to donor or recipient age. This allowed us to assess the impact of these factors on the incidence of rejection events, immunologic graft failure, and overall graft failure. Neither univariate nor multivariate analysis of this medium risk population indicated a relationship. This is consistent with other studies that have studied rejection episodes 26 and graft failure in single and mixed diagnostic groups. [27] [28] [29] [30] [31] [32] Palay et al 33 observed an increased incidence of allograft rejections in an age-and diagnosis-matched adult cohort that received tissue from pediatric donors less than 6 years of age. They attributed this increased risk of rejection to higher histocompatibility antigen expression in very young donors. 34 The CDS did not include donor tissue less than 12 years of age.
ABO compatibility did not impact corneal graft rejection or failure when assessed at the end of the 12-year study period. These findings agreed with the 5-year results. 6, 35 The lack of concordance between the CDS ABO compatibility results and those noted in the Collaborative Corneal Transplant Study in which ABO incompatibility reduced corneal transplant survival 12 may be related to the intermediate-risk classification of CDS participants versus high risk in the Collaborative Corneal Transplant Study. 12 The trend toward higher rejection among ABO compatible pairs in the 10-year CDS multivariate analysis is likely just a spurious result of multiple comparisons that did not meet the criteria for statistical significance. Female gender, which seemed to be a risk factor for a rejection event in the 5-year analysis, did not remain significant in the 10-year data analysis. The evidence supporting a role for gender in graft rejection is also contradictory in other studies.
The lengthy follow-up period of the CDS allowed us to evaluate the impact of a rejection event on the long-term viability of corneal grafts. Those not experiencing a rejection event during the first 5 years of the study had a cumulative probability of graft failure of 12%. This increased to 22% for those with definite signs of rejection during the first 5 years. Slightly less than one-third of patients experiencing a definitive rejection reaction remained clear at the end of the study period. Further breakdown of this number showed that patients with PACE fared worse than those with Fuchs dystrophy (22% cleared vs. 37%). Once again, we see a poorer outcome for patients with an underlying diagnosis of PACE. We were unable to determine an explanation for this pattern, though the higher incidence of glaucoma in patients with PACE is very likely a contributing factor. To the best of our knowledge, there are no other studies that have focused on the long-term outcome of corneal transplants that have suffered rejection events.
The overall graft failure from all causes was 21%, with 34% being related to a definitive graft rejection and 60% being related to nonimmunologic causes. 1 The most common nonimmunologic cause of graft failure was endothelial decompensation, which included patients with probable (but not verifiable and therefore not included in the definite category) rejection reactions. Patients with PACE had a higher all-cause failure rate than those with Fuchs dystrophy 1 and a higher failure after a definitive rejection reaction. Patel et al, 8 Price et al, 25 and Williams et al 18 reported that their all-cause graft failure rates were 28% at 15 years, 7.5% at 3 years, and 40% and 54% at 10 and 15 years, respectively, and that 25%, 27.9%, and 34% of their respective graft failures were related to antecedent rejection reactions. Our results compare very favorably with these other studies. Patient populations in studies by Patel et al 8 and Price et al 25 were similar to ours, whereas the study by Williams et al 18 was a registry study that included regrafts and higher risk patients. These studies did not provide information about the clearance rate/response rate among patients who experienced a rejection reaction.
In summary, the CDS data documented a 75% 10-year cumulative probability of graft success in this intermediaterisk population. 1 The rejection and failure rates were lower than those reported in other studies of shorter duration or mixed patient populations. Patients who experienced a definite rejection event, however, frequently went on to graft failure (69%) raising important questions as to how we might change acute and long-term management of this group of patients. A distinct pattern was evident in which patients with PACE had a higher rate of rejection events, lower proportion of clearing, and corresponding higher failure after a rejection event, and higher all-cause failure rate than patients with underlying Fuchs dystrophy. Multivariate analysis of baseline recipient and donor factors indicated that the previous use of glaucoma medications and glaucoma filtering surgery was a significant risk factor related to a definite rejection event. A more comprehensive evaluation of this finding and the role that topical steroids or other antiinflammatory agents may have in reducing its effect on graft success would be worthwhile. Most studies answer or shed light on some questions and raise new ones-the CDS has definitely done this.
